These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Identification of cytoskeletal proteins as binding partners of Bri2 BRICHOS domain. Shimozawa M; Tigro H; Biverstål H; Shevchenko G; Bergquist J; Moaddel R; Johansson J; Nilsson P Mol Cell Neurosci; 2023 Jun; 125():103843. PubMed ID: 36935047 [TBL] [Abstract][Full Text] [Related]
10. BRICHOS domain associated with lung fibrosis, dementia and cancer--a chaperone that prevents amyloid fibril formation? Willander H; Hermansson E; Johansson J; Presto J FEBS J; 2011 Oct; 278(20):3893-904. PubMed ID: 21668643 [TBL] [Abstract][Full Text] [Related]
11. Recombinant Bri3 BRICHOS domain is a molecular chaperone with effect against amyloid formation and non-fibrillar protein aggregation. Poska H; Leppert A; Tigro H; Zhong X; Kaldmäe M; Nilsson HE; Hebert H; Chen G; Johansson J Sci Rep; 2020 Jun; 10(1):9817. PubMed ID: 32555390 [TBL] [Abstract][Full Text] [Related]
12. The BRICHOS domain, amyloid fibril formation, and their relationship. Knight SD; Presto J; Linse S; Johansson J Biochemistry; 2013 Oct; 52(43):7523-31. PubMed ID: 24099305 [TBL] [Abstract][Full Text] [Related]
13. BRICHOS domain of Bri2 inhibits islet amyloid polypeptide (IAPP) fibril formation and toxicity in human beta cells. Oskarsson ME; Hermansson E; Wang Y; Welsh N; Presto J; Johansson J; Westermark GT Proc Natl Acad Sci U S A; 2018 Mar; 115(12):E2752-E2761. PubMed ID: 29507232 [TBL] [Abstract][Full Text] [Related]
14. Identification of potential aggregation hotspots on Aβ42 fibrils blocked by the anti-amyloid chaperone-like BRICHOS domain. Kumar R; Le Marchand T; Adam L; Bobrovs R; Chen G; Fridmanis J; Kronqvist N; Biverstål H; Jaudzems K; Johansson J; Pintacuda G; Abelein A Nat Commun; 2024 Feb; 15(1):965. PubMed ID: 38302480 [TBL] [Abstract][Full Text] [Related]
15. Intravenous treatment with a molecular chaperone designed against β-amyloid toxicity improves Alzheimer's disease pathology in mouse models. Manchanda S; Galan-Acosta L; Abelein A; Tambaro S; Chen G; Nilsson P; Johansson J Mol Ther; 2023 Feb; 31(2):487-502. PubMed ID: 35982621 [TBL] [Abstract][Full Text] [Related]
16. Augmentation of Bri2 molecular chaperone activity against amyloid-β reduces neurotoxicity in mouse hippocampus in vitro. Chen G; Andrade-Talavera Y; Tambaro S; Leppert A; Nilsson HE; Zhong X; Landreh M; Nilsson P; Hebert H; Biverstål H; Fisahn A; Abelein A; Johansson J Commun Biol; 2020 Jan; 3(1):32. PubMed ID: 31959875 [TBL] [Abstract][Full Text] [Related]
17. S100A9 amyloid growth and S100A9 fibril-induced impairment of gamma oscillations in area CA3 of mouse hippocampus ex vivo is prevented by Bri2 BRICHOS. Andrade-Talavera Y; Chen G; Pansieri J; Arroyo-García LE; Toleikis Z; Smirnovas V; Johansson J; Morozova-Roche L; Fisahn A Prog Neurobiol; 2022 Dec; 219():102366. PubMed ID: 36273719 [TBL] [Abstract][Full Text] [Related]
18. BRI2 ectodomain affects Aβ42 fibrillation and tau truncation in human neuroblastoma cells. Del Campo M; Oliveira CR; Scheper W; Zwart R; Korth C; Müller-Schiffmann A; Kostallas G; Biverstal H; Presto J; Johansson J; Hoozemans JJ; Pereira CF; Teunissen CE Cell Mol Life Sci; 2015 Apr; 72(8):1599-611. PubMed ID: 25336154 [TBL] [Abstract][Full Text] [Related]
19. BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease. Del Campo M; Hoozemans JJ; Dekkers LL; Rozemuller AJ; Korth C; Müller-Schiffmann A; Scheltens P; Blankenstein MA; Jimenez CR; Veerhuis R; Teunissen CE Neurobiol Aging; 2014 Jul; 35(7):1596-604. PubMed ID: 24524963 [TBL] [Abstract][Full Text] [Related]